Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end-stage diabetic nephropathy

被引:25
作者
Boeger, Carsten A.
Stubanus, Mike
Haak, Thomas
Goetz, Angela K.
Christ, Johanna
Hoffmann, Ute
Riegger, Guenther A. J.
Kraemer, Bernhard K.
机构
[1] Klinikum Univ Regensburg, Klin & Poliklin Innere Med 2, D-93053 Regensburg, Germany
[2] Univ Freiburg Klinikum, Abt Nephrol & Allgemeinmed, Med Klin 4, Freiburg, Germany
关键词
cardiovascular mortality; ESRD; genetics; MTHFR (C677T) polymorphism; progression of diabetic nephropathy; type 2 diabetes mellitus;
D O I
10.1093/ndt/gfl512
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 [基础医学]; 1002 [临床医学]; 100602 [中西医结合临床];
摘要
Background. The MTHFR C677T single nucleotide polymorphism TT genotype is associated with increased levels of plasma homocysteine and possibly an effect on cardiovascular mortality. We evaluated the effect of C677T genotype on mortality in a large end-stage renal disease (ESRD) cohort. Methods. C677T genotype was determined in 439 Caucasians with end-stage diabetic nephropathy (DNP) (cases) recruited from 30 dialysis centres in Southern Germany. A total of 482 type 2 diabetes patients without DNP (no microalbuminuria) at inclusion served as a genotype control collective. Patients were prospectively followed for 4 years. Primary endpoint was all-cause mortality. Results. In contrast to controls, the genotype distribution in cases was not in Hardy-Weinberg equilibrium (HWE, P = 0.003), due to a less than expected number of patients with the TT genotype. The requirements of HWE were met in cases with < 2 years dialysis therapy prior to study inclusion (n = 219). TT genotype was associated with a decreased body mass index (P = 0.002) and long diabetes duration in dialysis patients (P = 0.03). However, TT genotype was not associated with an increased risk of all-cause or cardiac mortality in the total dialysis collective or the subgroup. Also, we observed no association of MTHFR genotype with cardiovascular morbidity in cases or controls (P > 0.05), or with an increased rate of progression to novel microalbuminuria. Conclusion. MTHFR 677TT genotype was significantly underrepresented in patients with ESRD in our study, but was not associated with premature mortality in these patients. We found no evidence for survival bias due to C677T genotype in the ESRD cohort, or bias due to genetically determined accelerated progression to novel microalbuminuria in the controls. However, we cannot exclude that the TT genotype protects from progression from microalbuminuria to more advanced stages of DNP, or that TT genotype is associated with premature mortality before a patient progresses to ESRD.
引用
收藏
页码:154 / 162
页数:9
相关论文
共 33 条
[1]
Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) [J].
Adler, AI ;
Stevens, RJ ;
Manley, SE ;
Bilous, RW ;
Cull, CA ;
Holman, RR .
KIDNEY INTERNATIONAL, 2003, 63 (01) :225-232
[2]
Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease [J].
Anderson, JL ;
Muhlestein, JB ;
Horne, BD ;
Carlquist, JF ;
Bair, TL ;
Madsen, TE ;
Pearson, RR .
CIRCULATION, 2000, 102 (11) :1227-1232
[3]
The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multicentre prospective study [J].
Aucella, F ;
Margaglione, M ;
Grandone, E ;
Vigilante, M ;
Gatta, G ;
Forcella, M ;
Ktena, M ;
De Min, A ;
Salatino, G ;
Procaccini, DA ;
Stallone, C ;
Gesualdo, L .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (02) :382-386
[4]
RANTES gene polymorphisms redict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients [J].
Böger, CA ;
Fischereder, M ;
Deinzer, M ;
Aslanidis, C ;
Schmitz, G ;
Stubanus, M ;
Banas, B ;
Krüger, B ;
Riegger, GAJ ;
Krämer, BK .
ATHEROSCLEROSIS, 2005, 183 (01) :121-129
[5]
C-reactive protein as predictor of death in end-stage diabetic nephropathy:: Role of peripheral arterial disease [J].
Böger, CA ;
Götz, A ;
Stubanus, M ;
Banas, B ;
Deinzer, M ;
Krüger, B ;
Holmer, SR ;
Schmitz, G ;
Riegger, GAJ ;
Krämer, BK .
KIDNEY INTERNATIONAL, 2005, 68 (01) :217-227
[6]
Böger CA, 2005, EUR J MED RES, V10, P161
[7]
BOGER CA, 2006, IN PRESS INT J CLIN
[8]
Homocysteine lowering and cardiovascular events after acute myocardial infarction [J].
Bonaa, KH ;
Njolstad, I ;
Ueland, PM ;
Schirmer, H ;
Tverdal, A ;
Steigen, T ;
Wang, H ;
Nordrehaug, JE ;
Arnesen, E ;
Rasmussen, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (15) :1578-1588
[9]
Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients - A prospective study [J].
Bostom, AG ;
Shemin, D ;
Verhoef, P ;
Nadeau, MR ;
Jacques, PF ;
Selhub, J ;
Dworkin, L ;
Rosenberg, IH .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) :2554-2558
[10]
HYPERHOMOCYSTEINEMIA AND TRADITIONAL CARDIOVASCULAR-DISEASE RISK-FACTORS IN END-STAGE RENAL-DISEASE PATIENTS ON DIALYSIS - A CASE-CONTROL STUDY [J].
BOSTOM, AG ;
SHEMIN, D ;
LAPANE, KL ;
MILLER, JW ;
SUTHERLAND, P ;
NADEAU, M ;
SEYOUM, E ;
HARTMAN, W ;
PRIOR, R ;
WILSON, PWF ;
SELHUB, J .
ATHEROSCLEROSIS, 1995, 114 (01) :93-103